How Much Molly Is Too Much: What Current Evidence Tells Us

There is no universally safe MDMA dose. The effects and risks depend not only on the amount taken but also on factors such as body weight, metabolism, medications, other substances, health, temperature and hydration. Clinical studies can establish how people respond to particular doses under controlled conditions, but they cannot define a dose that is safe for everyone. Drug checking can reduce uncertainty about the amount and contents of a sample, but it cannot make MDMA use risk free.

Body weight can be used as one reference point, but it cannot determine a safe or individually appropriate MDMA dose. Clinical research has used weight-adjusted doses, and Drugchecking Berlin currently provides 1.3 mg/kg for women and 1.5 mg/kg for men as a dosage orientation for people with little or no tolerance. These figures are guidance from a specific drug checking service, not universal medical thresholds. Research also shows substantial individual variation in MDMA exposure and effects even after accounting for body weight.

The 1.3–1.5 mg/kg figures currently used by Drugchecking Berlin are harm-reduction reference values for oral MDMA-HCl use in people with little or no tolerance. They are not derived from a single clinical study establishing a universally safe dose. Clinical research has used similar weight-adjusted doses, but study doses are designed to investigate MDMA under controlled conditions rather than provide recreational dosing recommendations.

The 120 mg figure is commonly used as a reference point because some harm-reduction organisations describe 80–120 mg as a common adult MDMA dose. It is not a universal safety limit. In fact, current drug checking data show that many tablets contain substantially more than 120 mg, which is why pill strength should not be assumed from its appearance or reputation. The Loop reported in 2026 that 9 in 10 tested pills contained more than 120 mg of MDMA.

There is no single international definition of a high-strength MDMA pill. 150 mg of MDMA per tablet is commonly used as a high-strength threshold in European drug monitoring and drug-alert systems. This is a classification used to describe unusually strong tablets, not a universal point at which an individual will experience toxicity. Some tablets currently found through drug checking contain considerably more than 150 mg.

Yes. Pills that look identical can contain very different amounts of MDMA or completely different substances. Drugchecking Berlin specifically warns that colour, logo, weight and dimensions cannot establish a tablet's chemical composition and reports visually identical tablets with substantially different MDMA contents. This is why appearance alone cannot be used to estimate strength.

No. Weighing a whole pill tells you its total mass, not how much of that mass is MDMA. Tablets also contain binders, fillers and potentially other active substances, so two pills with the same weight can have very different MDMA contents. Chemical analysis or quantitative drug checking is needed to estimate the actual MDMA content.

The MDMA QTest® is a quantitative test designed to estimate the MDMA concentration in a sample. Depending on the sample and testing method, results can be expressed as MDMA content or concentration. The current miraculix method uses a small sample of a pill, powder or crystal and produces a colour reaction that is compared with a reference scale. The test is designed to provide information about how much MDMA is present, rather than simply whether MDMA is detected.

The MDMA QTest can provide information about MDMA concentration, but this should not be treated as a guarantee of purity or safety. A quantitative result tells you how much MDMA is estimated to be present in the tested sample, while other substances may still be present. The QTest manual also notes that unknown substances can cross-react with the reagents and affect the quantitative result.

Homogenising a sample helps make the portion tested more representative of the whole sample. MDMA and other substances may not be distributed evenly throughout a pressed tablet or crystal mixture. If only a small, unrepresentative portion is tested, the result may not accurately reflect the composition of the remaining material. Crushing and thoroughly mixing the sample before taking the test portion can therefore reduce sampling error.

Yes. Some medications can alter MDMA's effects, metabolism or both. For example, the SSRI paroxetine has been shown to inhibit CYP2D6 (an enzyme involved in the metabolism of MDMA) and increase MDMA plasma concentrations while reducing some of its subjective and physiological effects. Other medications can interact with MDMA through different mechanisms, so there is no single rule that applies to all medicines. Anyone taking medication should discuss potential interactions with a doctor or pharmacist rather than assuming that a particular combination is safe.

Research suggests that biological sex can influence some aspects of MDMA's effects, although it does not provide a basis for universally safe male or female doses. Controlled research has found differences in subjective effects and MDMA concentrations, while women appear to have a higher risk of MDMA-associated hyponatraemia in particular circumstances. This is one reason why body weight or sex alone cannot reliably predict an individual's response.

MDMA can interfere with the body's ability to regulate water and sodium levels. Drinking large amounts of water can dilute the sodium concentration in the blood, causing hyponatraemia. In severe cases, this can lead to brain swelling, seizures, loss of consciousness and death. Research has shown that MDMA can increase the fall in blood sodium associated with water loading, so drinking excessive amounts of water is not a safe way to prevent dehydration.

Redosing adds more MDMA while the first dose may still be active in the body. MDMA also has complex pharmacokinetics, with dose-dependent changes in its concentrations and metabolism. Human studies have found substantial variation in MDMA exposure between individuals, while experimental research has demonstrated nonlinear accumulation at relevant concentrations. As a result, taking an additional dose does not necessarily produce a predictable proportional increase in effects.

The duration varies between individuals, but controlled research provides a useful overall estimate. In a pooled analysis of nine clinical studies involving 166 healthy participants, the average duration of subjective MDMA effects was 4.2 hours, with individual results ranging from 1.4 to 8.2 hours. Peak effects generally occur earlier, around 1–2 hours after oral administration. After-effects such as fatigue, sleep disturbance or changes in mood can continue after the main effects have ended.